LARIMAR THERAPEUTICS, INC. Operating Cash Flow
LARIMAR THERAPEUTICS, INC. (LRMR) reported Operating Cash Flow of -$88.64 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-04
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$44.03M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$44.61M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-06-30 was -$19.38M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for the quarter ending 2025-03-31 was -$26.54M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$113.20M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$70.76M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$33.46M.
- LARIMAR THERAPEUTICS, INC. net cash provided by (used in) operating activities for fiscal 2022 was -$27.57M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 3 month as first filed | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 6 month as first filed | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 9 month as first filed | Net Cash Provided by (Used in) Operating Activities 12 month | Net Cash Provided by (Used in) Operating Activities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$44.03M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$88.64M 10-Q · filed 2026-08-04 | ||||||
| 2026-03-31 | -$44.61M 10-Q · filed 2026-05-14 | |||||||
| 2025-12-31 | -$113.20M 10-K · filed 2026-03-19 | |||||||
| 2025-06-30 | -$19.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04 | -$45.92M 10-Q · filed 2026-08-04 | -$67.74M derived: sum of 3 quarters · filed 2026-08-04 | -$92.28M derived: sum of 4 quarters · filed 2026-08-04 | ||||
| 2025-03-31 | -$26.54M 10-Q · filed 2026-05-14 | -$48.35M derived: sum of 2 quarters · filed 2026-05-14 | -$72.90M derived: sum of 3 quarters · filed 2026-05-14 | -$86.89M derived: sum of 4 quarters · filed 2026-05-14 | ||||
| 2024-12-31 | -$21.82M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$46.36M derived: sum of 2 quarters · filed 2026-03-19 | -$60.35M derived: sum of 3 quarters · filed 2026-03-19 | -$70.76M 10-K · filed 2026-03-19 | ||||
| 2024-09-30 | -$24.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$38.53M derived: sum of 2 quarters · filed 2025-08-14 | -$48.95M 10-Q · filed 2024-10-30 | -$58.29M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-06-30 | -$13.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -$24.40M 10-Q · filed 2025-08-14 | -$33.74M derived: sum of 3 quarters · filed 2025-08-14 | -$42.94M derived: sum of 4 quarters · filed 2025-08-14 | ||||
| 2024-03-31 | -$10.41M 10-Q · filed 2025-04-30 | -$19.75M derived: sum of 2 quarters · filed 2025-04-30 | -$28.95M derived: sum of 3 quarters · filed 2025-04-30 | -$36.32M derived: sum of 4 quarters · filed 2025-04-30 | ||||
| 2023-12-31 | -$9.34M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | -$18.54M derived: sum of 2 quarters · filed 2025-03-24 | -$25.91M derived: sum of 3 quarters · filed 2025-03-24 | -$33.46M 10-K · filed 2025-03-24 | ||||
| 2023-09-30 | -$9.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-30 | -$16.57M derived: sum of 2 quarters · filed 2024-10-30 | -$24.12M 10-Q · filed 2024-10-30 | -$30.79M derived: sum of 4 quarters · filed 2024-10-30 | ||||
| 2023-06-30 | -$7.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$14.92M 10-Q · filed 2024-08-08 | -$21.59M derived: sum of 3 quarters · filed 2024-08-08 | -$27.47M derived: sum of 4 quarters · filed 2024-08-08 | ||||
| 2023-03-31 | -$7.55M 10-Q · filed 2024-05-09 | -$14.22M derived: sum of 2 quarters · filed 2024-05-09 | -$20.10M derived: sum of 3 quarters · filed 2024-05-09 | -$27.59M derived: sum of 4 quarters · filed 2024-05-09 | ||||
| 2022-12-31 | -$6.67M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | -$12.55M derived: sum of 2 quarters · filed 2024-03-14 | -$20.04M derived: sum of 3 quarters · filed 2024-03-14 | -$27.57M 10-K · filed 2024-03-14 | ||||
| 2022-09-30 | -$5.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$13.36M derived: sum of 2 quarters · filed 2023-11-14 | -$20.90M 10-Q · filed 2023-11-14 | -$28.82M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | -$7.49M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$15.02M 10-Q · filed 2023-08-10 | -$22.94M derived: sum of 3 quarters · filed 2023-08-10 | -$35.14M derived: sum of 4 quarters · filed 2023-08-10 | ||||
| 2022-03-31 | -$7.53M 10-Q · filed 2023-05-15 | -$15.45M derived: sum of 2 quarters · filed 2023-05-15 | -$27.65M derived: sum of 3 quarters · filed 2023-05-15 | -$38.43M derived: sum of 4 quarters · filed 2023-05-15 | ||||
| 2021-12-31 | -$7.92M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14 | -$20.12M derived: sum of 2 quarters · filed 2023-03-14 | -$30.90M derived: sum of 3 quarters · filed 2023-03-14 | -$42.10M 10-K · filed 2023-03-14 | ||||
| 2021-09-30 | -$12.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$22.98M derived: sum of 2 quarters · filed 2022-11-10 | -$34.19M 10-Q · filed 2022-11-10 | -$44.04M derived: sum of 4 quarters · filed 2022-11-10 | ||||
| 2021-06-30 | -$10.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | -$21.99M 10-Q · filed 2022-08-11 | -$31.84M derived: sum of 3 quarters · filed 2022-08-11 | -$43.07M derived: sum of 4 quarters · filed 2022-08-11 | ||||
| 2021-03-31 | -$11.21M 10-Q · filed 2022-05-12 | -$21.06M derived: sum of 2 quarters · filed 2022-05-12 | -$32.28M derived: sum of 3 quarters · filed 2022-05-12 | -$44.48M derived: sum of 4 quarters · filed 2022-05-12 | ||||
| 2020-12-31 | -$9.86M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-25 | -$21.08M derived: sum of 2 quarters · filed 2022-03-25 | -$33.28M derived: sum of 3 quarters · filed 2022-03-25 | -$42.20M 10-K · filed 2022-03-25 | ||||
| 2020-09-30 | -$11.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$23.42M derived: sum of 2 quarters · filed 2021-11-12 | -$32.34M 10-Q · filed 2021-11-12 | -$40.25M derived: sum of 4 quarters · filed 2021-11-12 | ||||
| 2020-06-30 | -$12.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$21.12M 10-Q · filed 2021-08-12 | -$29.03M derived: sum of 3 quarters · filed 2021-08-12 | -$34.85M derived: sum of 4 quarters · filed 2021-08-12 | ||||
| 2020-03-31 | -$8.92M 10-Q · filed 2021-05-10 | -$4.62M 10-Q · filed 2020-05-07 | -$16.83M derived: sum of 2 quarters · filed 2021-05-10 | -$22.66M derived: sum of 3 quarters · filed 2021-05-10 | -$19.15M derived: sum of 4 quarters · filed 2021-05-10 | |||
| 2019-12-31 | -$7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-04 | -$13.73M derived: sum of 2 quarters · filed 2021-03-04 | -$10.23M derived: sum of 3 quarters · filed 2021-03-04 | -$22.70M 10-K · filed 2021-03-04 | -$40.78M 10-K · filed 2020-03-05 | |||
| 2019-09-30 | -$5.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | -$2.32M derived: sum of 2 quarters · filed 2020-11-12 | -$14.79M 10-Q · filed 2020-11-12 | -$30.98M 10-Q · filed 2019-11-06 | -$26.62M derived: sum of 4 quarters · filed 2020-11-12 | |||
| 2019-06-30 | $3.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-14 | -$8.96M 10-Q · filed 2020-08-14 | -$23.25M 10-Q · filed 2019-08-08 | -$20.80M derived: sum of 3 quarters · filed 2020-08-14 | -$33.88M derived: sum of 4 quarters · filed 2020-08-14 | |||
| 2019-03-31 | -$12.47M 10-Q · filed 2020-05-07 | -$24.30M derived: sum of 2 quarters · filed 2020-05-07 | -$37.38M derived: sum of 3 quarters · filed 2020-05-07 | -$50.69M derived: sum of 4 quarters · filed 2020-05-07 | ||||
| 2018-12-31 | -$11.83M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$24.91M derived: sum of 2 quarters · filed 2020-03-05 | -$38.22M derived: sum of 3 quarters · filed 2020-03-05 | -$51.49M 10-K · filed 2020-03-05 | ||||
| 2018-09-30 | -$13.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | -$26.39M derived: sum of 2 quarters · filed 2019-11-06 | -$39.65M 10-Q · filed 2019-11-06 | -$49.49M derived: sum of 4 quarters · filed 2020-03-05 | ||||
| 2018-06-30 | -$13.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08 | -$26.58M 10-Q · filed 2019-08-08 | -$36.41M derived: sum of 3 quarters · filed 2020-03-05 | |||||
| 2018-03-31 | -$13.27M 10-Q · filed 2019-05-09 | -$23.10M derived: sum of 2 quarters · filed 2020-03-05 | ||||||
| 2017-12-31 | -$9.84M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-05 | -$43.78M 10-K · filed 2020-03-05 | ||||||
| 2017-09-30 | -$33.95M 10-Q · filed 2018-11-09 | |||||||
| 2017-06-30 | -$21.86M 10-Q · filed 2018-08-09 | |||||||
| 2016-12-31 | -$51.98M 10-K · filed 2019-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |